Somite Therapeutics and OmniaBio Collaborate to Advance AI-Driven Cell Therapy for Duchenne Muscular Dystrophy

Somite Therapeutics, a tech-bio company focused on AI-powered cell therapies, has announced a partnership with OmniaBio Inc., a global cell and gene therapy CDMO. The collaboration aims to advance Somite’s flagship program, SMT-M01, a cell replacement therapy targeting Duchenne muscular dystrophy (DMD). This partnership will leverage OmniaBio’s expertise in induced pluripotent stem cells (iPSCs) to optimize the production of cells, enhance regulatory compliance, and accelerate the therapy’s clinical development.

The collaboration focuses on process optimization, including master cell banking, cell differentiation, and drug product manufacturing. By integrating AI with scientific advancements, Somite aims to streamline manufacturing and improve cost efficiency, ultimately enhancing the effectiveness of its therapies. OmniaBio will provide crucial support in transforming cell biology while ensuring the efficient development of Somite’s cell therapy programs.

With an anticipated Phase 1/2 trial set to begin within 18-24 months, the collaboration will also fuel Somite’s AlphaStem platform, a data-driven foundation model that optimizes therapy creation. The SMT-M01 program, targeting DMD, promises to offer significant improvements in muscle function and quality of life for affected individuals.

Somite Therapeutics, founded in 2023, is revolutionizing stem cell biology by harnessing AI to develop scalable therapies for diseases such as muscular dystrophy, diabetes, and obesity. OmniaBio, as part of CCRM, specializes in regenerative medicine and cell therapy manufacturing, offering cutting-edge solutions to drive global advancements in healthcare.

This collaboration marks a significant step toward the future of AI-driven cell therapy, with the potential to transform patient outcomes and bring groundbreaking treatments to market.

For more information visit: https://www.prnewswire.com/news-releases/somite-therapeutics-and-omniabio-inc-announce-collaboration-to-advance-somites-cell-therapy-flagship-program-302241525.html